Advances in nuclear medicine-based molecular imaging in head and neck squamous cell carcinoma

Abstract

Head and neck squamous cell carcinomas (HNSCCs) are often aggressive, making advanced disease very difficult to treat using contemporary modalities, such as surgery, radiation therapy, and chemotherapy. However, targeted therapy, e.g., cetuximab, an epidermal growth factor receptor inhibitor, has demonstrated survival benefit in HNSCC patients with locoregional failure or distant metastasis. Molecular imaging aims at various biomarkers used in targeted therapy, and nuclear medicine-based molecular imaging is a real-time and non-invasive modality with the potential to identify tumor in an earlier and more treatable stage, before anatomic-based imaging reveals diseases. The objective of this comprehensive review is to summarize recent advances in nuclear medicine-based molecular imaging for HNSCC focusing on several commonly radiolabeled biomarkers. The preclinical and clinical applications of these candidate imaging strategies are divided into three categories: those targeting tumor cells, tumor microenvironment, and tumor angiogenesis. This review endeavors to expand the knowledge of molecular biology of HNSCC and help realizing diagnostic potential of molecular imaging in clinical nuclear medicine.

Keywords: Cancer-associated fibroblasts; Epidermal growth factor receptor; Head and neck squamous cell carcinoma; Molecular imaging; Nuclear medicine; Programmed cell death ligand 1; Prostate-specific membrane antigen; Somatostatin receptor.

Fig. 1

Schematic diagram showing the common subsites for head and neck squamous cell carcinoma, and various categories of target for nuclear medicine-based molecular imaging. (Created using BioRender.com)